A vaccine against ALK-based resistance mutations induces immune responses against all of its targeted antigen in patients ...

Pfizer (NYSE:PFE) has entered a global oncology partnership with Innovent Biologics worth up to $10.5b, focused on up to 12 ...

Lung cancer is the leading cause of cancer death worldwide, with various subtypes affecting millions of people each year. Among these, ALK-positive lung cancer frequently strikes younger people who ...

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...

Seven-year analysis from Pfizer’s Lorbrena CROWN trial shows longest progression-free survival reported to date in advanced non-small cell lung cancer: New York Monday, June 1, ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

Is Zykadia Right for Me? Your health care provider will consider what type of lung cancer you have and whether it has spread to help choose the right treatment for you. Zykadia is used for NSCLC that ...

A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical ...

The Lung Cancer Research Foundation, in partnership with patients, survivors, caregivers, loved ones, industry partners and ...

– ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the ...

Lilly's Retevmo demonstrates 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer: Indianapolis ...

Ensartinib offers improved progression-free survival for ALK-positive NSCLC compared with crizotinib, with a median PFS of 25.8 months vs 12.7 months. Adverse events with ensartinib are mostly mild, ...